Vulvar Cancer Clinical Trials
Vulvar cancer clinical trials are ongoing at Moffitt Cancer Center, the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida. Through these important research studies, we are able to make promising new therapies available to our patients, allowing them to be among the first to benefit from exciting breakthroughs in cancer treatment.
Many vulvar cancer clinical trials focus on new treatment modalities to evaluate their effectiveness as compared to the current standard of care. At any given time, Moffitt may be conducting clinical trials of new:
- Drugs
- Combinations of existing treatments
- Approaches to radiation therapy
- Surgical techniques
- Ways to manage symptoms
- Prevention methods
Prospective clinical trial participants sometimes express concerns regarding the safety or the effectiveness of the drugs or therapies being used in clinical trials. However, it’s important to note that any therapies in clinical trials have already undergone rigorous testing prior to the clinical trial phase. To ensure patient safety, a clinical trial is required to conform to strict guidelines, and its compliance is continually monitored by an Institutional Review Board (IRB), an independent ethics committee formed with the goal of protecting patients.
Due, in part, to our outstanding national reputation, Moffitt has attracted some of the most talented scientists in the nation. These experts have come together to collaborate closely in a stimulating intellectual environment that fosters outstanding research initiatives. Through our multispecialty approach, we continue to gain ground in advancing the knowledge base about cancer and utilizing clinical trials to translate novel laboratory discoveries into viable treatment options for current and future cancer patients.
To learn about the vulvar cancer clinical trials available at Moffitt and discuss your potential participation with a clinical trial navigators, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online.
-
Clinical Trials
CLINICAL TRIAL 20870
Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian Tumors
Condition: Gynecological Tumor
Intervention: Aspirin/Placebo (); Avastin (Bevacizumab); Bevacizumab (); Paraplatin (carboplatin); Taxol (paclitaxel); carboplatin (); paclitaxel ()
CLINICAL TRIAL 22102
A Phase 1/2, First in Human Multicenter Study of Emi-Le in Patients with Solid Tumors
Condition: Multiple
Intervention: Emiltatug Ledadotin (); XMT-1660 ()
CLINICAL TRIAL 23067
Phase 2 Study of Alpelisib and Fulvestrant for PIK3CA-mutated Estrogen Receptor (ER)-positive Endometrioid Endometrial Cancers
Condition: Gynecological Tumor
Intervention: Alpelisib (); Faslodex (fulvestrant); fulvestrant ()
CLINICAL TRIAL 23143
Trends and Outcomes in HIV-positive Patients Undergoing Treatment for Invasive or Preinvasive Cervical and Other Gynecologic Neoplasias
Condition: Gynecological Tumor
Intervention:
CLINICAL TRIAL 23176
A Phase 2, randomised, open label, multicentre study of an intraperitoneal alpha-emitting radionuclide therapy (Radspherin®) in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, with peritoneal metastasis that are homologous recombination proficient and scheduled to undergo neoadjuvant chemotherapy and interval debulking surgery
Condition: Gynecological Tumor
Intervention: Radspherin ()
CLINICAL TRIAL 23362
DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer
Condition: Gynecological Tumor
Intervention: Paraplatin (carboplatin); Pembrolizumab (Keytruda); Rilvegostomig (); T-Dxd (); Taxol (paclitaxel); carboplatin (); paclitaxel ()
CLINICAL TRIAL 23380
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod CAR T Protducts in Heterozygous HLA-A*02 Adult with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Condition: Thoracic
Intervention: A2B543 (); A2B694 (); IL-2 (Interleukin-2); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
CLINICAL TRIAL 23636
A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors
Condition: Gynecological Tumor
Intervention: XmAb541 ()
CLINICAL TRIAL 23645
PHASE 1 DOSE ESCALATION AND EXPANSION STUDY OF XB628 AS A SINGLE AGENT AND IN COMBINATION WITH ZANZALINTINIB IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Condition: Multiple
Intervention: XB628 (); Zanzalintinib ()
CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Olomorasib (); Sotorasib (); Trametinib (); VVD-159642 ()
CLINICAL TRIAL 24028
OMNIRAY, A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496, a GRPR-Targeted Radioligand Therapy, in Adults with GRPR-Positive Advanced Solid Tumors
Condition: Multiple
Intervention: Abemaciclib (); Anastrozole (); Arimadex (Anastrozole); Aromasin (Exemestane); Exemestane (); Faslodex (fulvestrant); Femara (Letrozole); Imlunestrant (); LY2835219 (Abemaciclib); LY4257496 (); LY4257529 (); Letrozole (); Xeloda (capecitabine); capecitabine (); fulvestrant ()
CLINICAL TRIAL 24081
A Phase 1 Study of SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR, in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma
Condition: Multiple
Intervention: SynKIR-110 ()
CLINICAL TRIAL 24190
A Dose Escalation and Dose Optimization Phase 1a/1b Study to Evaluate Safety, Tolerability and Dosimetry of Radioligand Therapy with LY4337713 in Adults with FAP-Positive Solid Tumors (FiREBOLT)
Condition: Multiple
Intervention: LY4337713 (); [18F] FAPI-74 (); [Ga-68]-FAPI-46 ()
CLINICAL TRIAL 24236
A Phase 1 First-in-Human Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: 5-fluorouracil (); Alimta (Pemetrexed); ERAS-0015 (); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Oxaliplatin (); Panitumumab (); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); Taxotere (docetaxel); Vectibix (Panitumumab); carboplatin (); cisplatin (); docetaxel (); eloxatin (Oxaliplatin); gemcitabine (); leucovorin ()
CLINICAL TRIAL 24299
A study of a mutant-selective inhibitor, CGT6297, in patients with advanced solid tumors harboring PIK3CA mutations
Condition: Multiple
Intervention: CGT6297 ()
Treatment